| 000 | 01667cam a2200337 a 4500 | ||
|---|---|---|---|
| 003 | EG-GiCUC | ||
| 005 | 20250223030433.0 | ||
| 008 | 110623s2010 ua h f m 000 0 eng d | ||
| 040 |
_aEG-GiCUC _beng _cEG-GiCUC |
||
| 041 | 0 | _aeng | |
| 049 | _aDeposite | ||
| 097 | _aM.Sc | ||
| 099 | _aCai01.11.18.M.Sc.2010.Ah.N | ||
| 100 | 0 | _aAhmed Abdulhameed Mohammad | |
| 245 | 1 | 0 |
_aNovel therapeutics in myelodysplastic syndromes / _cAhmed Abdulhameed Mohammad ; Supervised Mona M. Elkassas , Mona Elhuseiny Abufarha |
| 246 | 1 | 5 | _aبحث حول الأساليب العلاجية الحديثة لمتلازمة خلل النخاع |
| 260 |
_aCairo : _bAhmed Abdulhameed Mohammad , _c2010 |
||
| 300 |
_a123P. : _bfacsimiles ; _c25cm |
||
| 502 | _aThesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Internal Medicine | ||
| 520 | _aMyelodysplastic syndromes ( MDS ) entails a series of hematologic conditions characterized by chronic cytopenias and abnormal cellular maturation . Although supportive treatment remains the main approach advances in understanding pathogenesis of MDS have generated novel strategies for management Refinements in determining critical prognostic parameters have led to improved understanding the natural history and treatment of MDS | ||
| 530 | _aIssued also as CD | ||
| 653 | 4 | _aEpigenetic modifiers | |
| 653 | 4 | _aMyelodysplastic syndromes | |
| 653 | 4 | _aNovel therapies | |
| 700 | 0 |
_aMona Elhuseiny Abufarha , _eSupervisor |
|
| 700 | 0 |
_aMona Mohamed Elkassas , _eSupervisor |
|
| 856 | _uhttp://172.23.153.220/th.pdf | ||
| 905 |
_aFatma _eCataloger |
||
| 905 |
_aNazla _eRevisor |
||
| 942 |
_2ddc _cTH |
||
| 999 |
_c34677 _d34677 |
||